Changing the antibiotic playbook to catch an ESKAPE artist
Nearly a century ago, a single colony of Staphylococcus aureus (S. aureus) helped launch the antibiotic age. In 1928, Alexander Fleming returned to his London lab to find that a stray mold had wiped out the Staphylococcus growing on one of his plates. The accident gave the world penicillin, ushering in the age of biomedicine and ensuring that an infected cut or scrape would not be fatal.
In the late 1920s, the rise of a single Staphylococcus aureus colony sparked the antibiotic age. Alexander Fleming's accidental discovery of penicillin marked the beginning of modern medicine, combating previously fatal infections caused by the same bacterium. However, today Staphylococcus aureus, particularly Methicillin-resistant S. aureus (MRSA), is deemed one of the most dangerous superbugs by the World Health Organization.
This "ESKAPE" group of six pathogens is notorious for their ability to evade multiple antibiotics, causing skin, bloodstream, and surgical-implant infections. Antimicrobial resistance (AMR) has become a silent pandemic, threatening the effectiveness of routine medical procedures due to untreatable infections. The 2024 Global Research on Antimicrobial Resistance (GRAM) study predicts that drug-resistant infections could directly cause over 39 million deaths between 2025 and 2050, with resistant Staphylococcus infections alone responsible for about 130,000 deaths.
South Asia, including India, is anticipated to bear the greatest burden, with roughly 11.8 million deaths.
Researchers at the Indian Institute of Technology Gandhinagar (IITGN) have devised a novel laboratory-made molecule to combat S. aureus by targeting and disabling an essential enzyme, thymidine kinase (TK). This enzyme is crucial for bacteria's DNA replication and repair processes, making it a promising drug target as most antibiotics do not specifically target TK.
The team collaborated with researchers from Jamia Millia Islamia, Jamia Hamdard, Xi'an Jiaotong-Liverpool University, and Sushen Medicamentos to develop a new approach. By analyzing the crystal structure of S. aureus thymidine kinase, the researchers identified a unique pocket to target, away from the enzyme's natural chemistry.
They created a new molecule using a thiazole ring and a sulfonamide group, resulting in a potent compound named DSA3. Computer simulations indicated that DSA3 fits perfectly into the ATP-binding pocket of the enzyme, blocking its function. Laboratory tests confirmed that DSA3 reduces thymidine kinase activity by half and inhibits bacterial growth and kills Staphylococcus aureus, making it a promising starting scaffold for further development.
Written by urgent.news from Phys.org's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
